What Has Been the Growth of the Neuralgia Treatment Market So Far?
The neuralgia treatment market has seen considerable growth due to a variety of factors.
• The market size for neuralgia treatment has witnessed robust growth in the past few years. It's projected to escalate from $2.3 billion in 2024 to $2.44 billion in 2025, marking a compound annual growth rate (CAGR) of 6.0%.
The growth during the historical period can be traced back to the increasing incidence of neuralgia, amplified awareness about neuropathic pain, surge in cases of chronic pain, availability of higher disposable income, and various government initiatives.
How Will the Neuralgia Treatment Market?
The neuralgia treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market for neuralgia treatment is anticipated to witness substantial expansion in the coming years. The projected market value is expected to reach $3.13 billion by 2029, with a compound annual growth rate (CAGR) of 6.4%.
Factors contributing to this growth during the forecast period include the aging population, rising instances of diabetes, heightened healthcare spending, and the emergence of new therapeutic approaches. Key trends to look out for during the forecast period include progression in pain management techniques, the introduction of innovative products, incorporation of digital health, and the development of new drug delivery systems.
Which Factors Are Boosting Growth In The Neuralgia Treatment Market?
The increasing incidence of chronic conditions, particularly diabetes, is predicted to drive the expansion of the neuralgia treatment market. Chronic illnesses are those that persist for a year or more, require ongoing medical attention, limit daily activities, or both. Diabetes is a long-term metabolic disorder marked by elevated levels of blood glucose, also known as blood sugar. Diabetic neuropathy, a type of nerve damage common in diabetes patients, can be managed with neuralgia treatment. For example, as per the World Health Organization in September 2023, a Switzerland-based UN agency, 41 million people died due to non-communicable diseases (NCDs) or chronic illnesses, making up 74% of all the deaths worldwide. Hence, the escalating incidents of chronic diseases, including diabetes, are fueling the growth of the neuralgia treatment market.
The Expansion of the Neuralgia Treatment Market Fueled by an Expected Increase in Surgical Procedures
What Key Areas Define The Segmentation Of The Global Neuralgia Treatment Market?
The neuralgia treatment market covered in this report is segmented –
1) By Treatment: Drug Based, Surgeries
2) By Indication: Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia
3) By Distribution channels: Drug Stores, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Use: Hospitals And Clinics, Ambulatory Surgery Centers, Other End-Users
Subsegments:
1) By Drug Based: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2) By Surgeries: Nerve Block Procedures, Decompression Surgery, Neurectomy, Spinal Cord Stimulation
Pre-Book The Neuralgia Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Neuralgia Treatment Market?
Key players in the neuralgia treatment market are concentrating on the creation of innovative products and solutions to uphold their market standing. In April 2023, GlaxoSmithKline Pharmaceuticals Ltd., a company based in India, introduced Shingrix, the first ever non-live and recombinant subunit vaccine worldwide, specifically in India. This vaccine is primarily targeted at preventing shingles and post-herpetic neuralgia in adults over 50 years of age, and is given through two intramuscular doses. Shingrix amalgamates the antigen glycoprotein E with the adjuvant system AS01B, leading to a powerful and enduring immunological response that can effectively combat the age-related deterioration of the immune system. Clinical studies have proven that this vaccine is 97% successful in warding off shingles in adults. Additionally, it provides effective protection against post-herpetic neuralgia, a painful sequelae of shingles.
Who Are the Key Players In The Neuralgia Treatment Market?
Major companies operating in the neuralgia treatment market are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Abbott Laboratories
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Astellas Pharma Inc.
• Biogen Inc.
• Daiichi Sankyo Company Limited
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Limited
• Horizon Therapeutics
• Purdue Pharma
• Dr. Reddy's Laboratories
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Zydus Lifesciences Ltd.
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Glenmark Pharmaceuticals
• Tonix Pharmaceuticals.
What Is The Most Dominant Region In The Neuralgia Treatment Market?
North America was the largest region in the neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuralgia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
